By demonstrating the role of legumain in TGF-β1-induced inhibition of osteoblast maturation, our study has important implications for bone disorders associated with aberrant TGF-β1 signaling and suggests legumain as a potential target for therapeutic interventions. This evidence concerns the gene LGMN and bone disorder.